Carregando empresa
Just reported
Q3 2026 results
From Tempus AI's results release of 2 de novembro de 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 411,5M
+23% y/y
+7,6% q/qGuided
—
No guide given
EPS, GAAP
Actual
-US$ 0,08
Guided
—
No guide given
Operating income, GAAP
Actual
-US$ 56,9M
Guided
—
No guide given
Company outlook
Full year 2026
- RevenueUS$ 1,6B – US$ 1,605B+26% y/y Unchanged
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Tempus AI is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Health Information Services
Graded A or B and worth $2B or more: A first, then the largest.
VEEVVeeva Systems Inc.US$ 49,4BA+
BTSGBrightSpring Health Services, Inc.US$ 14,4BA
HNGEHinge Health, Inc.US$ 9,9BA+
HQYHealthequity, Inc.US$ 8,5BA+
DOCSDoximity, Inc.US$ 5,9BB+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
BIIBBiogen Inc.28 de out. de 2026BAGraded B, now A
Como ganha dinheiro
- Diagnostic testing75%
- Data and applications25%
As participações na receita são estimativas para nine months ended September 30, 2026, não números de um relatório oficial.
Concorre com
O que vende6
Tempus|xT
A test of cancer tissue that looks for gene changes that may help doctors understand a cancer and choose treatment.
Tempus|xF
A blood test that looks for cancer-related genetic material circulating in the blood.
Tempus|xG
Tests that look for inherited gene changes linked to cancer risk and other inherited conditions.
Mostrar mais 3
Insights
De-identified patient records and research tools that drug and biotechnology companies use to study diseases and develop medicines.
TIME Trial program
A service that helps doctors and drug companies find patients who may qualify for clinical trials.
Next
Software that checks patient information to help care teams spot missed tests or follow-up needs in cancer and heart care.
Quem compra4
- Doctors, genetic counselors, and hospitals order tests for patients; insurers, government health programs, patients, or the ordering institution may pay.
- Pharmaceutical and biotechnology companies buy de-identified patient data, research tools, and analysis services.
- Drug companies pay for help identifying patients who may qualify for clinical trials.
- Academic research institutions buy laboratory testing and related research services.
Em que se apoia e o que pode quebrá-lo
Do que o negócio depende
- 1Its data business depends on continued access to patient records and permission to use and commercialize de-identified data.
- 2Clinical testing revenue depends in part on insurers and government health programs covering tests and paying enough to cover their cost.
- 3Laboratory testing relies on specialized instruments and materials from a limited number of suppliers, including some sole suppliers.
- 4The business depends on hospitals and other healthcare providers sharing data and using Tempus tests and software.
O que pode dar errado
- 1If Tempus loses access to patient data or cannot continue to use and license it, its research data and related services could be affected.
- 2Insurers or government health programs may decline to cover tests, reduce payment, or change reimbursement rules, affecting the amount Tempus collects for diagnostic work.
- 3Changes to rules for laboratory tests and AI-based medical tools could require additional approvals or oversight, delay products, or limit how Tempus can sell them.
Demonstrações financeiras completas →
Sobre a Tempus AI, Inc.
Tempus runs laboratory tests that examine a patient’s cancer or inherited health risks, then connects results with medical records and other patient information. It uses artificial intelligence (AI) to help doctors interpret results and identify possible treatments or clinical trials. Drug and biotechnology companies pay Tempus for de-identified patient data, research tools, and help finding patients for trials.
- Sede
- Chicago, Illinois
- Fundada em
- 2015
- Listada em
- Nasdaq
- Fim do exercício
- December 31
Construído a partir dos próprios documentos de Tempus AI, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
